AU Patent

AU2024222719A1 — Heterocyclic glp-1 agonists

Assigned to Gasherbrum Bio Inc · Expires 2025-08-21 · 1y expired

What this patent protects

The present disclosure relates generally to glucagon-like peptide-1 (GLP-1) agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

USPTO Abstract

The present disclosure relates generally to glucagon-like peptide-1 (GLP-1) agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024222719A1
Jurisdiction
AU
Classification
—
Expires
2025-08-21
Drug substance claim
No
Drug product claim
No
Assignee
Gasherbrum Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.